Medical Services

Clinical Trials at Englewood Hospital: Oncology

Kidney Cancer

EHMC IRB Study #: E-11-423

Principal Investigator:
Dr. Brian Kim
Tel: 201-894-3533
Email: bkim@fsahemonc.com

Study Coordinator:
Audrey Ades
Tel: 201-894-3603
Email: audrey.ades@ehmc.com

Sponsor:
National Cancer Institute - SWOG

Study Title:
EVEREST: Everolimus for Renal Cancer Ensuing Surgical Thearpy, a Phase III Study

Eligibility requirements:
Patients who are at least 18 years old with confirmed renal cell carcinoma, who have undergone a full resection with negative margins, and who have not received any prior treatment.

Study objectives:
To compare recurrence-free survival in renal carcinoma patients randomly assigned to one year of everolimus vs. one year of placebo after nephrectomy or partial nephrectomy.

Summary of procedures:
Patients will be randomized to receive either everolimus or placebo daily by mouth for nine, six-week cycles.  Assessments for recurrence will be done every three cycles (18 weeks) for 54 weeks, then every 6 months for two years, then annually thereafter until recurrence Year 10, whichever occurs first.